Literature DB >> 22505407

High-resolution crystal structures of factor XIa coagulation factor in complex with nonbasic high-affinity synthetic inhibitors.

Xavier Fradera1, Bert Kazemier, Emma Carswell, Andrew Cooke, Arthur Oubrie, William Hamilton, Maureen Dempster, Stephan Krapp, Susanna Nagel, Anja Jestel.   

Abstract

Factor XI (FXI) is a key enzyme in the coagulation pathway and an attractive target for the development of anticoagulant drugs. A small number of high-resolution crystal structures of FXIa in complex with small synthetic inhibitors have been published to date. All of these ligands have a basic P1 group and bind exclusively in the nonprime side of the active site of FXIa. Here, two structures of FXIa in complex with nonbasic inhibitors that occupy both the prime and nonprime sides of the active site are presented. These new structures could be valuable in the design and optimization of new FXIa synthethic inhibitors.
© 2012 International Union of Crystallography. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22505407      PMCID: PMC3325807          DOI: 10.1107/S1744309112009037

Source DB:  PubMed          Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun        ISSN: 1744-3091


  20 in total

Review 1.  Factor Xa inhibitors: next-generation antithrombotic agents.

Authors:  Donald J P Pinto; Joanne M Smallheer; Daniel L Cheney; Robert M Knabb; Ruth R Wexler
Journal:  J Med Chem       Date:  2010-09-09       Impact factor: 7.446

2.  Design and synthesis of macrocyclic indoles targeting blood coagulation cascade Factor XIa.

Authors:  Stephen Hanessian; Andreas Larsson; Tomas Fex; Wolfgang Knecht; Niklas Blomberg
Journal:  Bioorg Med Chem Lett       Date:  2010-10-08       Impact factor: 2.823

3.  More than a simple lipophilic contact: a detailed thermodynamic analysis of nonbasic residues in the s1 pocket of thrombin.

Authors:  Bernhard Baum; Menshawy Mohamed; Mohamed Zayed; Christof Gerlach; Andreas Heine; David Hangauer; Gerhard Klebe
Journal:  J Mol Biol       Date:  2009-05-03       Impact factor: 5.469

4.  Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Jack Hirsh; Robert Raschke
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

5.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

Review 6.  Structural and functional features of factor XI.

Authors:  D Gailani; S B Smith
Journal:  J Thromb Haemost       Date:  2009-07       Impact factor: 5.824

7.  Clavatadine A, a natural product with selective recognition and irreversible inhibition of factor XIa.

Authors:  Malcolm S Buchanan; Anthony R Carroll; Deborah Wessling; Michael Jobling; Vicky M Avery; Rohan A Davis; Yunjiang Feng; Yafeng Xue; Linda Oster; Tomas Fex; Johanna Deinum; John N A Hooper; Ronald J Quinn
Journal:  J Med Chem       Date:  2008-06-26       Impact factor: 7.446

8.  Oral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of change.

Authors:  Jennifer Carreiro Zikria; Jack Ansell
Journal:  Curr Opin Hematol       Date:  2009-09       Impact factor: 3.284

9.  Discovery and evaluation of potent P1 aryl heterocycle-based thrombin inhibitors.

Authors:  Mary Beth Young; James C Barrow; Kristen L Glass; George F Lundell; Christina L Newton; Janetta M Pellicore; Kenneth E Rittle; Harold G Selnick; Kenneth J Stauffer; Joseph P Vacca; Peter D Williams; Dennis Bohn; Franklin C Clayton; Jacquelynn J Cook; Julie A Krueger; Lawrence C Kuo; S Dale Lewis; Bobby J Lucas; Daniel R McMasters; Cynthia Miller-Stein; Beth L Pietrak; Audrey A Wallace; Rebecca B White; Bradley Wong; Youwei Yan; Philippe G Nantermet
Journal:  J Med Chem       Date:  2004-06-03       Impact factor: 7.446

10.  REFMAC5 for the refinement of macromolecular crystal structures.

Authors:  Garib N Murshudov; Pavol Skubák; Andrey A Lebedev; Navraj S Pannu; Roberto A Steiner; Robert A Nicholls; Martyn D Winn; Fei Long; Alexei A Vagin
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18
View more
  7 in total

1.  Sulfonated non-saccharide molecules and human factor XIa: Enzyme inhibition and computational studies.

Authors:  Rami A Al-Horani; Elnaz Parsaeian; Mariam Mohammad; Madhusoodanan Mottamal
Journal:  Chem Biol Drug Des       Date:  2022-04-11       Impact factor: 2.873

Review 2.  Recent advances in the discovery and development of factor XI/XIa inhibitors.

Authors:  Rami A Al-Horani; Daniel K Afosah
Journal:  Med Res Rev       Date:  2018-05-04       Impact factor: 12.944

Review 3.  Tetrazoles via Multicomponent Reactions.

Authors:  Constantinos G Neochoritis; Ting Zhao; Alexander Dömling
Journal:  Chem Rev       Date:  2019-02-01       Impact factor: 60.622

4.  Sulfated pentagalloylglucoside is a potent, allosteric, and selective inhibitor of factor XIa.

Authors:  Rami A Al-Horani; Pooja Ponnusamy; Akul Y Mehta; David Gailani; Umesh R Desai
Journal:  J Med Chem       Date:  2013-01-28       Impact factor: 7.446

Review 5.  Factor XIa inhibitors: A review of the patent literature.

Authors:  Rami A Al-Horani; Umesh R Desai
Journal:  Expert Opin Ther Pat       Date:  2016       Impact factor: 6.674

6.  Creating novel activated factor XI inhibitors through fragment based lead generation and structure aided drug design.

Authors:  Ola Fjellström; Sibel Akkaya; Hans-Georg Beisel; Per-Olof Eriksson; Karl Erixon; David Gustafsson; Ulrik Jurva; Daiwu Kang; David Karis; Wolfgang Knecht; Viveca Nerme; Ingemar Nilsson; Thomas Olsson; Alma Redzic; Robert Roth; Jenny Sandmark; Anna Tigerström; Linda Öster
Journal:  PLoS One       Date:  2015-01-28       Impact factor: 3.240

7.  Interactions outside the proteinase-binding loop contribute significantly to the inhibition of activated coagulation factor XII by its canonical inhibitor from corn.

Authors:  Vera A Korneeva; Mikhail M Trubetskov; Alena V Korshunova; Sofya V Lushchekina; Vladimir N Kolyadko; Olga V Sergienko; Vladimir G Lunin; Mikhail A Panteleev; Fazoil I Ataullakhanov
Journal:  J Biol Chem       Date:  2014-04-04       Impact factor: 5.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.